StatLab Medical Products — Cyborg Score 7/10

Strong
Medical Devices - Anatomic Pathology Consumables & Diagnostic Equipment

Strategic Profile

Through acquisitions and expanded manufacturing capabilities, StatLab is making the supply chain for pre analytical pathology products shorter, more stable, and more reliable. StatLab's most recent deal was a Buyout/LBO with Histoserve on 13-Aug-2025. The company has pursued vertical integration through strategic acquisitions in the UK and domestically, expanding its product portfolio and manufacturing footprint.

Cyborg Score Rationale

StatLab demonstrates solid competitive positioning as a specialized niche player in anatomic pathology consumables with 50 years of operating history. Recent acquisitions and manufacturing expansion signal growth momentum, though private status and limited public financial data constrain visibility into scale and profitability.

Top Insights

  • Aggressive vertical integration strategy through acquisitions of CellPath, Polyscientific R&D, Histoserve, and Scientific Device Laboratory expanding product portfolio across histology, cytology, microbiology, and archiving
  • Significant domestic manufacturing expansion with new 35,000 sq ft Arlington facility (2023) for cassette production and archiving services, reducing offshore dependency
  • Over 500 employees globally across US, UK, and Germany with ISO13485-certified operations, indicating quality infrastructure for regulated medical device market
  • Customer-centric differentiation through supply chain reliability and responsive service noted across customer testimonials, addressing critical lab pain points

Named Competitors

  • BioGenex Laboratories — Histology and immunohistochemistry diagnostics
  • CellPath — Cassettes and histology products with archiving solutions
  • Cardinal Health — Broad pathology supply distribution

Recent Developments

  • (August 2025) Completed Buyout/LBO acquisition of Histoserve
  • (2024) Acquired Scientific Device Laboratory expanding into microbiology with printed diagnostic slides and TB testing products
  • (2024) Acquired Polyscientific R&D including Histology Control Systems, strengthening stain and control slide capabilities
  • (2023) Opened new 35,000 sq ft injection molding facility in Arlington, Texas for cassette manufacturing

Open the full interactive StatLab Medical Products report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →